Jun Ma

TL;DR: It is suggested that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-positive NSCLC, and was associated with more favourable tolerability than standard chemotherapy.

TL;DR: The results confirm that the addition of concomitant chemotherapy to radiotherapy significantly improves survival in patients with locoregionally advanced nasopharyngeal carcinoma.

TL;DR: The significant OS benefit observed in patients treated with EGFR-TKI emphasises its contribution to improving survival of EGFR mutation-positive advanced non-small-cell lung cancer patients, suggesting that erlotinib should be considered standard first-line treatment of EGfr mutant patients and EGFR -TKI treatment following first- line therapy also brings significant benefits to those patients.

TL;DR: In this paper, a CT-MRI fusion atlas of organs at risk (OARs) for nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy, in order to help reach a consensus on interpretations of OARs delineation.

TL;DR: The pretreatment AGR may represent a simple, potentially useful predictive biomarker for evaluating the long-term prognosis of patients with undifferentiated NPC.